4th Quarter - Report

CELGENE CORPORATION for CELGENE CORPORATION

Period 4th Quarter 2011 Filed Jan 19, 2012 Signed by Anne Marie Finley, Vice President, Government Relations and Public Policy

Official filing
Firm
CELGENE CORPORATION
Client
CELGENE CORPORATION
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

- H.R. 1249/ S. 23, "Leahy-Smith America Invents Act", issues regarding patent reform. - PDUFA reauthorization - H.R.2672, S.1423, "Preserving Access to Orphan Drugs Act of 2011", regarding all provisions - Issues regarding PPACA implementation.

LobbyistCovered position, as disclosed
ANNE MARIE FINLEY —

Contacted: SENATE; Treasury, Dept of; Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 23 (112th), S. 1423 (112th), H.R. 2672 (112th), H.R. 1249 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.